clinical trial · NCT07351968
A Phase Ib Study to Evaluate the Efficacy and Safety of HRS-2129 in Patients With Knee Osteoarthritis
Shandong Suncadia Medicine Co., Ltd.·phase1·recruiting·n = 200
Moderate Pain in Knee OsteoarthritisSevere Pain in Knee OsteoarthritisHRS-2129 TabletCelecoxib capsuleCelecoxib Capsule PlaceboHRS-2129 Tablet Placebo
brief summary
Primary Objective: To explore the effectiveness of different doses of HRS-2129 in the treatment of patients with moderate to severe pain in knee osteoarthritis. Secondary Objectives: To evaluate the safety of different doses of HRS-2129 for the treatment of patients with moderate to severe pain in knee osteoarthritis; To evaluate the population pharmacokinetic profile of HRS-2129 in patients with knee osteoarthritis.
started
Mar 10, 2026
primary completion
Aug 1, 2026
completion
Aug 1, 2026
last updated
Mar 19, 2026
official title
A Multicenter, Randomized, Double-blind, Agent-positive and Placebo-controlled, Parallel-group Phase Ib Study to Evaluate the Efficacy and Safety of HRS-2129 in Patients With Knee Osteoarthritis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol